Nervous Disorder TRIZ Cases

Anti-TMEM106B antibodies reduce TMEM106B activity to treat neurodegenerative disorders without increasing therapeutic regimen complexity.

H-NOX proteins accumulate in the hypoxic penumbra to reduce infarct volume and inflammation while avoiding reactive oxygen species generation.

Antibodies binding amyloid beta residues 29-40 clear toxic peptides without cross-reacting with physiological APP, preventing cerebral hemorrhages.

METRNL growth factor mediates neuroprotection by enhancing neuronal survival, addressing limitations of traditional drug therapies for neurological disorders.

Self-organizing neuromesodermal progenitor cells form complete functional neuromuscular junctions, resolving the complexity of separate cell type cultures.

Ghrelin analogues reduce uncontrolled inflammation and tissue damage by inhibiting pro-inflammatory cytokine expression.

Antibodies targeting citrullinated epitopes resolve specificity trade-offs while reducing inflammatory severity and joint erosion.

19-nor neuroactive steroids reduce toxicity and side effects while maintaining therapeutic efficacy for CNS disorders.

Palladium-catalyzed condensation of 7-methoxy-1-naphthol avoids expensive aromatization steps and laborious purification.

Combining RXR agonists with thyroid hormones treats autoimmune diseases.

Humanized anti-IL-23p19 antibodies resolve confusing cytokine therapy results by targeting the unique p19 subunit to inhibit IL-23-induced cytokine production.

NLRP3 inhibitors reduce bladder inflammation and neuroinflammation by blocking caspase-1 activity to treat chronic pain.

Targeting specific phospho-epitopes resolves intra-neuronal aggregation challenges while improving therapeutic specificity.

LOX inhibitors treat fibrosis and cancer by altering extracellular matrix properties to reduce drug resistance.

Cyclopeptide dual agonists activate peripheral opioid and NPFF receptors, reducing respiratory suppression and tolerance risks.

DFMO prodrugs metabolize to release active difluoromethylornithine, inhibiting ornithine decarboxylase and reducing gastrointestinal side effects.

An acrylic polymer adhesive matrix with non-volatile coadjuvants prevents drug loss during manufacturing drying steps while maintaining adhesive strength.

Indolin-2-one derivatives address schizophrenia negative symptoms and cognitive dysfunction by interacting with multiple neurotransmitter systems.

Ultrasound-triggered nanoparticle expansion enables targeted drug delivery to specific brain regions, reducing systemic side effects.

Formula I compounds resolve off-target toxicity by selectively blocking Cav2.3 channels for neuroprotection.

Pridopidine counteracts Tetrabenazine-induced motor side effects while maintaining therapeutic efficacy in Huntington's disease treatment.

Alkyl urea compounds activate NAMPT to increase cellular NAD+ levels, addressing inadequate modulation of existing strategies.

Cas13 ribonucleoproteins with specific gRNA spacers reduce toxic RNA levels, addressing targeting difficulties in neurological disease treatments.

Merging diverse leukocyte subtypes into a single culture reduces processing time and preserves cell viability compared to isolated isolation methods.

Combining anti-CSF1R antibodies with PD-1 inhibitors overcomes resistance from immunosuppressive macrophages to enhance CD8+ T cell efficacy.

Targeting the SMG7-Upf1 interface with novel compounds inhibits nonsense mediated RNA decay, addressing toxicity issues from existing therapies like gentamicin.

Three-dimensional stem cell clusters form via hydrophobic detachment, resolving low yield bottlenecks in vascular endothelial cell production.

Non-steroidal estrogen receptor beta agonists activate signaling pathways to promote oligodendrocyte precursor proliferation and differentiation.

A competitive ligand binding assay detects neutralizing antibodies using labeled biotherapeutic and soluble receptor reagents.

Naphthalene carboxamide compounds modulate the M1 receptor via positive allosteric mechanisms, reducing side effects associated with direct agonists.

Metal coordination chemistry stabilizes distinct pharmacophores in a single entity, preventing agent interference and enhancing synergistic delivery efficacy.

Prodrug glutamine antagonists release DON in target cells, resolving toxicity and CNS penetration limits.

A cross-linkable PEG derivative and polysaccharide agent form injectable macroporous hydrogels through simultaneous gelation and phase separation.

A therapeutic composition combines natural extracts to stimulate endogenous heparan sulfate production.

Calcium-release stabilizing molecules stabilize calcium release mechanisms in brain cells, addressing the complexity of treating multiple pathological factors.

NSI-189 treats depression in cognitively impaired patients via EEG biomarker selection, resolving trial-and-error medication matching.

Delta-2-tubulin serves as a biomarker to identify individuals at risk of developing chemotherapy-induced peripheral neuropathy.

CD200 antagonists block immune suppression pathways, enabling targeted depletion of CD200-positive cells for cancer and autoimmune treatment.

Chlorobutanol preservative enhances peptide bioavailability across the blood-brain barrier, resolving low absorption in neurodegenerative treatments.

D-amino acid peptides inhibit N-type neuronal calcium channels through specific binding and protease resistance.

Short-lived peptidomimetics replace antibodies to increase drug delivery efficiency while reducing immunogenicity and toxicity.

An optimized assay detects JC virus antibodies using highly purified viral-like particles and labeled reagents.

Carbamate compounds modulate MAGL and ABHD6 enzymes through localized structural features, resolving selectivity trade-offs over FAAH to treat pain and cancer.

TRAIL analogs and anti-DR5 antibodies target activated pancreatic stellate cells, resolving the trade-off between treatment effectiveness and invasiveness.

Modular pyrimidinecarboxamide design enables SX-682 to inhibit CXCR1/2 receptors, addressing synthesis complexity while treating inflammatory disorders.